Evaluation of a Novel Dual Antifibrotic and Proregenerative Strategy to Facilitate Improved Functional Outcomes in the Treatment of Volumetric Muscle Loss
Abstract
The overall objective of the proposed work is to evaluate the safety and efficacy of administration of mCAR513 for: mitigating the fibrotic wound healing response to volumetric muscle loss (VML), and to enhance the efficacy of leading, near term regenerative therapies in promoting reconstitution of skeletal muscle volume and end-organ neuromusculoskeletal function following VML injury thereby facilitating improved outcomes, namely sustained readiness and lethality of the fighting force. During this reporting period, we encountered unexpected issues in accessing mCAR513 due to supply chain issues as a result of the COVID-19 pandemic. In response, we are pursuing alternative options to replacemCAR513 as the antifibrotic intervention for this proposal.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1193691
Entities
People
- Christopher L Dearth
Organizations
- Henry M. Jackson Foundation for the Advancement of Military Medicine